HSD17B13 and hepatocellular carcinoma: These genes along with other protective variants in hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13), mitochondrial amidoxime reducing component 1 (MARC1) and cell death-inducing DFFA-like effector B (CIDEB) can be integrated to form polygenic risk scores which are associated with outcomes such as liver fat accumulation, cirrhosis, and the risk of hepatocellular carcinoma [38].